1. Home
  2. PSEC vs PHAT Comparison

PSEC vs PHAT Comparison

Compare PSEC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prospect Capital Corporation

PSEC

Prospect Capital Corporation

HOLD

Current Price

$2.12

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$11.52

Market Cap

969.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSEC
PHAT
Founded
2004
2018
Country
United States
United States
Employees
8
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
969.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PSEC
PHAT
Price
$2.12
$11.52
Analyst Decision
Sell
Strong Buy
Analyst Count
1
6
Target Price
$2.50
$19.83
AVG Volume (30 Days)
4.8M
1.2M
Earning Date
05-08-2026
04-30-2026
Dividend Yield
20.07%
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
N/A
$93.04
Revenue Next Year
N/A
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$2.11
$8.03
52 Week High
$3.48
$18.31

Technical Indicators

Market Signals
Indicator
PSEC
PHAT
Relative Strength Index (RSI) 36.56 53.92
Support Level $2.11 $9.95
Resistance Level $2.37 $11.65
Average True Range (ATR) 0.05 0.68
MACD -0.01 0.02
Stochastic Oscillator 5.82 46.35

Price Performance

Historical Comparison
PSEC
PHAT

About PSEC Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: